Oklahoma Rheumatic Disease Research Cores Center

俄克拉荷马州风湿病研究核心中心：总体 俄克拉荷马州风湿病研究中心(ORDRCC)的使命是支持和 优化基础、临床和分析科学家之间的互动，重点关注发病机制、预测和 风湿性疾病的预防和精准治疗选择。为了实现这一目标，ORDRCC 整合26名常设中心调查员、22名初级中心调查员(12名在内部，10名在外部 俄克拉荷马州)，以及12名潜在学者开发早期调查人员，并在 风湿病研究。ORDRCC基础设施、集合、核心和浓缩计划 帮助成功启动了33名前新调查员的独立职业生涯。此外，我们的CAP- 临床特征和生物资源库核心(CCBC)中的认证生物资源库提供访问 表型良好的横断面和纵向风湿病样本采集。ORDRCC- 支持的收藏和生物信息库基础设施是许多已建立的风湿病患者的关键资源 来自ORDRCC内部和通过风湿病机构间合作的疾病调查人员 和临床试验。在过去的4年中，CCBC人员协助了151项IRB研究方案， 招募了1,282名参与者，进行了2,648次队列研究访问，收集/处理了66,068份新的 样品等分，以及满足571个样品或数据请求。CCBC将继续扩大这些 收集，同时为临床研究单位提供研究招募和监管援助。此外， CCBC将开发一个创新中心来试验新的临床研究方法和一名临床试验者 发展计划。人类表型核心(HPC)提供经验丰富的技术人员， 标准操作程序、培训和分析专业知识，使ORDRCC调查人员能够使用 尖端技术，包括高维细胞术、单细胞多组学、转录组学、 空间多组学，以及对可溶性介体的高通量测试。CCBC和HPC共同实现了 通过整合临床和分子信息来识别风湿病调查和临床试验 用于创新研究设计的受试者的分子同质子集。行政核心 作为ORDRCC的中央管理和通信中心，并协调多个 学科充实计划，包括一项新的风湿病管道开发计划 代表不足的团体，一个指导计划，一个新的科学写作成功中心，以帮助调查人员 通过开发强大的手稿和竞争性的拨款申请，并扩大风湿病 研究座谈会，以增加ORDRCC科学家和其他人之间的联系和互动 NIAMS中心。ORDRCC通过以下方式共同促进和扩大风湿病的合作研究 提供职业发展、尖端技术、良好表型的临床数据，并促进 合作改善患者的生活。

Oklahoma Rheumatic Disease Research Cores Center: Overall The mission of the Oklahoma Rheumatic Disease Research Cores Center (ORDRCC) is to support and optimize interactions between basic, clinical, and analytical scientists focused on the pathogenesis, prediction, prevention, and precision therapeutic selection for rheumatic diseases. Towards this aim, the ORDRCC integrates 26 established center investigators, 22 junior center investigators (12 within and 10 outside Oklahoma), and 12 potential scholars to develop early-stage investigators with outstanding promise in rheumatic disease research. The ORDRCC infrastructure, collections, Cores and Enrichment Program have helped successfully launch the independent careers of 33 former New Investigators. In addition, our CAP- certified Biorepository within the Clinical Characterization and Biorepository Core (CCBC) provides access to well-phenotyped cross-sectional and longitudinal rheumatic disease sample collections. The ORDRCC- supported collections and biorepository infrastructure are critical resources for many established rheumatic disease investigators from within the ORDRCC and through inter-institutional rheumatic disease collaborations and clinical trials. In the past 4 years, the CCBC personnel have assisted with 151 IRB study protocols, recruitment of 1,282 participants, performed 2,648 cohort study visits and collected/processed 66,068 new sample aliquots, as well as fulfilled 571 samples or data requests. The CCBC will continue to expand these collections while providing clinical research units for study recruitment and regulatory assistance. Furthermore, the CCBC will develop an Innovation Hub to pilot novel clinical research approaches and a clinical trialist development program. The Human Phenotyping Core (HPC) provides experienced technical personal, standard operating procedures, training, and analytical expertise to empower ORDRCC investigators to use cutting-edge technologies, including high-dimensional cytometry, single-cell multi-omics, transcriptomics, spatial multi-omics, and high-throughput testing of soluble mediators. Together, the CCBC and HPC transform rheumatic disease investigation and clinical trials by integrating clinical and molecular information to identify molecularly homogeneous subsets of subjects for use in innovative study design. The Administrative Core serves as the central management and communication hub for the ORDRCC and co-ordinates a multi- disciplinary Enrichment Program, including a new rheumatic disease pipeline development program for underrepresented groups, a mentoring program, a new Science Writing Success Center to assist investigators with developing robust manuscripts and competitive grant applications, and Expanding Rheumatic Disease Research Colloquiums to increase outreach and forge interactions between ORDRCC scientists and other NIAMS Centers. Together, the ORDRCC facilitates and expands collaborative rheumatic disease research by providing career development, cutting-edge technologies, well-phenotyped clinical data, and fostering collaborations to improve patients’ lives.